Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 431

Results For "NAL"

5545 News Found

Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.
Policy | February 27, 2022

Cabinet approves Ayushman Bharat Digital Mission at an outlay of Rs 1,600 cr.

Citizens will be able to create their ABHA (Ayushman Bharat Health Account) numbers, to which their digital health records can be linked


New data reinforces efficacy of Tezspire
Biotech | February 27, 2022

New data reinforces efficacy of Tezspire

These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting


DiscGenics presents positive Phase1/2 study of Cell therapy for degenerative disc disease
Biotech | February 27, 2022

DiscGenics presents positive Phase1/2 study of Cell therapy for degenerative disc disease

Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection


VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod
Biotech | February 27, 2022

VBI’s 3-antigen Hepatitis B vaccine gets CHMP nod

If approved, PreHevbri will be the only approved 3-antigen hepatitis B vaccine for adults in the E.U.


LivaNova announces first patient implanted in OSPREY clinical study
Medical Device | February 27, 2022

LivaNova announces first patient implanted in OSPREY clinical study

Study to evaluate effectiveness of hypoglossal nerve stimulation


Daewoong  completes combination therapy of antidiabetic drug Enavogliflozin
News | February 27, 2022

Daewoong completes combination therapy of antidiabetic drug Enavogliflozin

Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy


HitGen completes research collaboration with MTPC
Biotech | February 27, 2022

HitGen completes research collaboration with MTPC

Collaboration with MTPC to discover novel hit compounds for multiple drug targets


Cantex and Harvard's Wyss Institute to expand development of Azeliragon
News | February 27, 2022

Cantex and Harvard's Wyss Institute to expand development of Azeliragon

Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.


Industry seeks favourable policy for India to move up the pharma value chain globally
Policy | February 27, 2022

Industry seeks favourable policy for India to move up the pharma value chain globally

N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry


IMI releases tamper evident caps with DoseID certified RFID
Digitisation | February 26, 2022

IMI releases tamper evident caps with DoseID certified RFID

Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs